Episode Details
Back to EpisodesDurvalumab’s Benefit in SCLC ”Beyond What We Might Have Expected”
Published 2 years, 2 months ago
Description
From ASCO 2024, Dr. Robert Figlin talks with Dr. Lauren Averett Byers from MD Anderson Cancer Center.
Durvalumab's Benefit in SCLC "Beyond What We Might Have Expected"